{"id":50844,"date":"2022-11-14T23:02:09","date_gmt":"2022-11-14T22:02:09","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/foxo-technologies-postpones-third-quarter-2022-earnings-report-and-conference-call\/"},"modified":"2022-11-14T23:02:09","modified_gmt":"2022-11-14T22:02:09","slug":"foxo-technologies-postpones-third-quarter-2022-earnings-report-and-conference-call","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/foxo-technologies-postpones-third-quarter-2022-earnings-report-and-conference-call\/","title":{"rendered":"FOXO Technologies Postpones Third Quarter 2022 Earnings Report and Conference Call"},"content":{"rendered":"
\n

MINNEAPOLIS–(BUSINESS WIRE)–FOXO Technologies Inc.<\/a> (NYSEAM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science, today announced that it is postponing its earnings conference call.\n<\/p>\n

\nThe Company will issue a press release announcing the new date and time for the postponed earnings call.\n<\/p>\n

\nAbout FOXO Technologies Inc. (\u201cFOXO\u201d)<\/b>\n<\/p>\n

\nFOXO is a technology platform company focused on commercializing longevity science through products and services that serve the life insurance industry. FOXO’s epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging. FOXO seeks to modernize the life insurance industry by simplifying the consumer underwriting journey with saliva-based biomarkers and enhancing life insurance\u2019s consumer value proposition with the FOXO Longevity Report\u2122<\/span>. For more information about FOXO, visit www.foxotechnologies.com<\/a>. For more information about FOXO LIFE, visit www.foxolife.com<\/a>. For investor information and updates, visit https:\/\/foxotechnologies.com\/investors\/<\/a>.\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nThis press release contains certain forward-looking statements for purposes of the \u201csafe harbor\u201d provisions under the United States Private Securities Litigation Reform Act of 1995. Any statements other than statements of historical fact contained herein, including statements as to future results of operations and financial position, planned products and services, business strategy and plans, objectives of management for future operations of FOXO, market size and growth opportunities, competitive position and technological and market trends, are forward-looking statements. Such forward-looking statements include, but not limited to, expectations, hopes, beliefs, intentions, plans, prospects, financial results or strategies regarding FOXO and the future held by management teams of FOXO, the future financial condition and performance of FOXO and the products and markets and expected future performance and market opportunities of FOXO. These forward-looking statements generally are identified by the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccould,\u201d \u201cexpect,\u201d \u201cestimate,\u201d \u201cfuture,\u201d \u201cintend,\u201d \u201cstrategy,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cstrategy,\u201d \u201copportunity,\u201d \u201cplan,\u201d project,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cproject,\u201d \u201cpredict,\u201d \u201cscales,\u201d \u201crepresentative of,\u201d \u201cvaluation,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201cwill be,\u201d \u201cwill continue,\u201d \u201cwill likely result,\u201d and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the risk that changes in the competitive and highly regulated industries in which FOXO operates, variations in operating performance across competitors, changes in laws and regulations affecting FOXO\u2019s business, and changes in the combined capital structure, (ii) the ability to implement FOXO\u2019s business plans, forecasts, and other expectations, (iii) potential inability of FOXO to establish or maintain relationships required to advance its goals or to achieve its commercialization and development plans, (iv) the enforceability of FOXO\u2019s intellectual property, including its patents and the potential infringement on the intellectual property rights of others, and (v) the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry or in the markets or industries in which FOXO\u2019s prospective customers operate, including the highly regulated insurance industry. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties described in the \u201cRisk Factors\u201d filed with the SEC, and risks and uncertainties indicated in the Registration Statement, including those set forth under \u201cRisk Factors\u201d therein, and other documents filed or to be filed by FOXO from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FOXO assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nContacts \/ Investor Relations<\/b>
Cody Slach, Matthew Hausch
\n
Gateway Investor Relations
\n
(949) 574-3860
\n
FOXO@gatewayir.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MINNEAPOLIS–(BUSINESS WIRE)–FOXO Technologies Inc. (NYSEAM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science, today announced that it is postponing its earnings conference call. The Company will issue a press release announcing the new date and time for the postponed … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50844","6":"format-standard","7":"category-industry"},"yoast_head":"\nFOXO Technologies Postpones Third Quarter 2022 Earnings Report and Conference Call - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/foxo-technologies-postpones-third-quarter-2022-earnings-report-and-conference-call\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FOXO Technologies Postpones Third Quarter 2022 Earnings Report and Conference Call - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MINNEAPOLIS–(BUSINESS WIRE)–FOXO Technologies Inc. (NYSEAM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science, today announced that it is postponing its earnings conference call. The Company will issue a press release announcing the new date and time for the postponed ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/foxo-technologies-postpones-third-quarter-2022-earnings-report-and-conference-call\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-14T22:02:09+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/foxo-technologies-postpones-third-quarter-2022-earnings-report-and-conference-call\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/foxo-technologies-postpones-third-quarter-2022-earnings-report-and-conference-call\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"FOXO Technologies Postpones Third Quarter 2022 Earnings Report and Conference Call\",\"datePublished\":\"2022-11-14T22:02:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/foxo-technologies-postpones-third-quarter-2022-earnings-report-and-conference-call\\\/\"},\"wordCount\":699,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/foxo-technologies-postpones-third-quarter-2022-earnings-report-and-conference-call\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/foxo-technologies-postpones-third-quarter-2022-earnings-report-and-conference-call\\\/\",\"name\":\"FOXO Technologies Postpones Third Quarter 2022 Earnings Report and Conference Call - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-11-14T22:02:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/foxo-technologies-postpones-third-quarter-2022-earnings-report-and-conference-call\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/foxo-technologies-postpones-third-quarter-2022-earnings-report-and-conference-call\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/foxo-technologies-postpones-third-quarter-2022-earnings-report-and-conference-call\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FOXO Technologies Postpones Third Quarter 2022 Earnings Report and Conference Call\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FOXO Technologies Postpones Third Quarter 2022 Earnings Report and Conference Call - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/foxo-technologies-postpones-third-quarter-2022-earnings-report-and-conference-call\/","og_locale":"en_US","og_type":"article","og_title":"FOXO Technologies Postpones Third Quarter 2022 Earnings Report and Conference Call - Pharma Trend","og_description":"MINNEAPOLIS–(BUSINESS WIRE)–FOXO Technologies Inc. (NYSEAM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science, today announced that it is postponing its earnings conference call. The Company will issue a press release announcing the new date and time for the postponed ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/foxo-technologies-postpones-third-quarter-2022-earnings-report-and-conference-call\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-14T22:02:09+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/foxo-technologies-postpones-third-quarter-2022-earnings-report-and-conference-call\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/foxo-technologies-postpones-third-quarter-2022-earnings-report-and-conference-call\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"FOXO Technologies Postpones Third Quarter 2022 Earnings Report and Conference Call","datePublished":"2022-11-14T22:02:09+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/foxo-technologies-postpones-third-quarter-2022-earnings-report-and-conference-call\/"},"wordCount":699,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/foxo-technologies-postpones-third-quarter-2022-earnings-report-and-conference-call\/","url":"https:\/\/pharma-trend.com\/en\/foxo-technologies-postpones-third-quarter-2022-earnings-report-and-conference-call\/","name":"FOXO Technologies Postpones Third Quarter 2022 Earnings Report and Conference Call - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-11-14T22:02:09+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/foxo-technologies-postpones-third-quarter-2022-earnings-report-and-conference-call\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/foxo-technologies-postpones-third-quarter-2022-earnings-report-and-conference-call\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/foxo-technologies-postpones-third-quarter-2022-earnings-report-and-conference-call\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"FOXO Technologies Postpones Third Quarter 2022 Earnings Report and Conference Call"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50844","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50844"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50844\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50844"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50844"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50844"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}